Lily Lee

1.3k total citations
25 papers, 889 citations indexed

About

Lily Lee is a scholar working on Pathology and Forensic Medicine, Oncology and Organic Chemistry. According to data from OpenAlex, Lily Lee has authored 25 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 7 papers in Oncology and 6 papers in Organic Chemistry. Recurrent topics in Lily Lee's work include Multiple Sclerosis Research Studies (8 papers), Polyomavirus and related diseases (6 papers) and Peripheral Neuropathies and Disorders (3 papers). Lily Lee is often cited by papers focused on Multiple Sclerosis Research Studies (8 papers), Polyomavirus and related diseases (6 papers) and Peripheral Neuropathies and Disorders (3 papers). Lily Lee collaborates with scholars based in United States, Germany and Austria. Lily Lee's co-authors include Thomas J. Walsh, Elias Anaissie, Nita L. Seibel, John R. Perfect, Jeffrey L. Silber, Mark J. DiNubile, Eric J. Bow, Gary Horwith, John W. Hiemenz and Annette C. Reboli and has published in prestigious journals such as New England Journal of Medicine, Neurology and Clinical Infectious Diseases.

In The Last Decade

Lily Lee

24 papers receiving 858 citations

Peers

Countries citing papers authored by Lily Lee

Since Specialization

Citations

This map shows the geographic impact of Lily Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lily Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lily Lee more than expected).

Fields of papers citing papers by Lily Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lily Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lily Lee. The network helps show where Lily Lee may publish in the future.

Co-authorship network of co-authors of Lily Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Lily Lee. A scholar is included among the top collaborators of Lily Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lily Lee. Lily Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbations in the ULTIMATE I and II Trials Comparing Ublituximab vs Teriflunomide (P3-6.001) 2024 ·Neurology ·Stephen Krieger, (unknown), Yihuan Xu, Hari P. Miskin, Lily Lee, Enrique Álvarez	0
2	Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (P6-4.010) 2022 ·Neurology ·Edward Fox, Lawrence Steinman, Hans‐Peter Hartung, Enrique Álvarez, Peiqing Qian, Sibyl Wray, Derrick Robertson, DeRen Huang, Krzysztof Selmaj, Daniel Wynn, Michael Weiss, (unknown), (unknown), (unknown), Lily Lee, Bruce Cree	1
3	Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies (P5-4.009) 2022 ·Neurology ·Bruce Cree, Edward Fox, Hans‐Peter Hartung, Enrique Álvarez, Peiqing Qian, Sibyl Wray, Derrick Robertson, DeRen Huang, Krzysztof Selmaj, Daniel Wynn, Michael Weiss, (unknown), (unknown), (unknown), Lily Lee, Lawrence Steinman	1
4	Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis 2022 ·New England Journal of Medicine ·Lawrence Steinman, Edward Fox, Hans‐Peter Hartung, Enrique Álvarez, Peiqing Qian, Sibyl Wray, Derrick Robertson, DeRen Huang, Krzysztof Selmaj, Daniel Wynn, Gary Cutter, (unknown), Yanzhi Hsu, Yihuan Xu, Michael Weiss, (unknown), (unknown), Lily Lee, Hari P. Miskin, Bruce Cree	111
5	Characterizing the ‘feel-good experience’ in Multiple Sclerosis Patients Treated With Natalizumab Or Other Therapies 2022 ·Neurodegenerative Disease Management ·John Foley, Regina Berkovich, Mark Gudesblatt, (unknown), Beth Schneider, Carl de Moor, (unknown), Lily Lee, (unknown), Robin L. Avila	5
6	Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study 2021 ·Advances in Therapy ·Jai Perumal, Roumen Balabanov, (unknown), Roger Chang, Laura J. Balcer, Steven Galetta, Denise I. Campagnolo, Robin L. Avila, Lily Lee, (unknown), Robert J. Fox	18
7	Updated Incidence of Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) and Its Relationship with Natalizumab Exposure Over Time (2815) 2020 ·Neurology ·Gavin Giovannoni, Ludwig Kappos, Joseph R. Berger, Gary Cutter, Robert J. Fox, Heinz Wiendl, Ih Chang, (unknown), Lily Lee, Stephanie Licata, Pei‐Ran Ho	6
8	The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis 2019 ·Multiple Sclerosis and Related Disorders ·John Foley, (unknown), (unknown), Karleyton C. Evans, Pei‐Ran Ho, Lily Lee, Rachna Kasliwal, Martin Stangel, Patrick Vermersch, Michael Hutchinson, Fabiana Marinelli, Karen Smirnakis	25
9	Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE 2019 ·BMC Neurology ·Jai Perumal, Robert J. Fox, Roumen Balabanov, Laura J. Balcer, Steven Galetta, (unknown), Sourav Santra, Christophe Hotermans, Lily Lee	40
10	Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis 2018 ·CNS Drugs ·Mark Gudesblatt, (unknown), (unknown), (unknown), Lori Fafard, Jeffrey Wilken, (unknown), Marijean Buhse, Sourav Santra, Christophe Hotermans, Lily Lee	15
11	Outcomes following natalizumab exposure throughout pregnancy in patients with relapsing multiple sclerosis (RMS) or Crohn’s disease (P1.362) 2017 ·Neurology ·(unknown), (unknown), Denise I. Campagnolo, Lily Lee	1
12	Truncated Aspidosperma Alkaloid-Like Scaffolds: Unique Structures for the Discovery of New, Bioactive Compounds 2011 ·Heterocycles ·John K. Snyder, Scott C. Benson, Lily Lee, Wanguo Wei, Feng Ni, (unknown), (unknown), Aaron B. Beeler, Ken Cheng, James Inglese, Smitha Kota, Virginia Takahashi, A. Donny Strosberg, John H. Connor, G. Guy Bushkin	3
13	Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif 2008 ·Bioorganic & Medicinal Chemistry Letters ·K. D. Kreutter, Tianbao Lu, Lily Lee, Edward C. Giardino, Sharmila Patel, Hui Huang, Guozhang Xu, Mark Fitzgerald, Barbara J. Haertlein, V. Mohan, Carl Crysler, Stephen Eisennagel, Malini Dasgupta, Martin McMillan, John Spurlino, Norman Huebert, Bruce E. Maryanoff, Bruce E. Tomczuk, Bruce P. Damiano, Mark R. Player	24
14	2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Lily Lee, K. D. Kreutter, Wenxi Pan, Carl Crysler, John Spurlino, Mark R. Player, Bruce E. Tomczuk, Tianbao Lu	35
15	Intramolecular Inverse Electron Demand Diels–Alder Reactions of Tryptamine with Tethered Heteroaromatic Azadienes 2000 ·Tetrahedron ·Scott C. Benson, Lily Lee, (unknown), John K. Snyder	67
16	Retrospective Analysis of the Dosage of Amphotericin B Lipid Complex for the Treatment of Invasive Fungal Infections 1999 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Peter Linden, Lily Lee, Thomas J. Walsh	23
17	Amphotericin B Lipid Complex for Invasive Fungal Infections: Analysis of Safety and Efficacy in 556 Cases 1998 ·Clinical Infectious Diseases ·Thomas J. Walsh, John W. Hiemenz, Nita L. Seibel, John R. Perfect, Gary Horwith, Lily Lee, Jeffrey L. Silber, Mark J. DiNubile, Annette C. Reboli, Eric J. Bow, John Lister, Elias Anaissie	461
18	Titles Of LIS Textbooks And Research Articles: A Bibliometric Study 1997 ·Malaysian Journal of Library & Information Science ·Kiran Kaur, Lily Lee, (unknown), (unknown)	3
19	Hydrotris(3,4-diphenyl-5-methylpyrazol-1-yl)borate: Control of Coordination Number via an Equatorial Substituent 1995 ·Inorganic Chemistry ·(unknown), Lily Lee, Brian S. Haggerty, Arnold L. Rheingold, Marc A. Walters	12
20	Ethical Issues Related to Research Involving Children 1991 ·Journal of Pediatric Oncology Nursing ·Lily Lee	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact